Results 161 to 170 of about 1,220,078 (316)

Toward More Open, Theoretically Grounded, and Sustainable Parental Involvement in Applied Behavior Analysis Interventions for Children with Autism Spectrum Disorder [Letter]

Psychology Research and Behavior Management
Shujuan Chen,1 Qing-Wei Chen2–4 1Department of Psychology, School of Education, Ningxia University, Yinchuan, People’s Republic of China; 2Lab of Light and Physio-Psychological Health, National Center for International Research on ...
Chen S, Chen QW
doaj  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters

Pharmacogenomics and Personalized Medicine
Marietta M Roth,1,2,* Aline Bencastro,1,2,* Christoph R Meier,1,2 Carola A Huber,3 Henriette E Meyer zu Schwabedissen,4 Samuel S Allemann,5,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical ...
Roth MM, Bencastro A, Meier CR, Huber CA, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data

Pharmacogenomics and Personalized Medicine
Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Julie D Moser,1 Henriette E Meyer zu Schwabedissen,5 Samuel S Allemann,6,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,
Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj  

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

If Drug Treatment Works So Well, Why Are So Many Drug Users in Prison? [PDF]

This paper examines the effectiveness of drug courts to reduce the size of the incarcerated drug-offending population using data from the Survey of Inmates in State Correctional Facilities and the Survey of Inmates in Local Jails.
Harold Pollack, Eric L. Sevigny, Peter Reuter   +2 more
core  

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

Reply: Including Vonoprazan With PPIs Challenges the Drug-Interaction Hypothesis. [PDF]

JACC Asia
Nishikura T, Yamamoto K, Watanabe H, Morimoto T, Kimura T.   +4 more
europepmc   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source